About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
- 2014 Rate Card & Production Specs
- 2013 Rate Card & Production Specs
- Advertising Due Dates
- BPA Statement
Statement of Purpose
Guidelines for Authors
Health Care and Law
Legal and policy changes implemented by the government affect all health care professionals, pharmacies, and insurers. The authors examine the signing of the Affordable Care Act (ACA), the hearings on the constitutionality of the ACA, and congressional efforts to reduce the nation’s health care–related deficits.
E. Paul Larrat, RPh, PhD; Rita M. Marcoux, RPh, MBA; and F. Randy Vogenberg, RPh, PhD
Clinical Approaches to the Improvement of Quality of Life
Pruritus is the most common skin disorder in elderly patients. The many causes of chronic itching, as well as topical, systemic, and nonpharmacological therapies, are reviewed.
Kenneth R. Cohen, PharmD, PhD; Jerry Frank, MD; Rebecca L. Salbu, PharmD, CGP; and Igor Israel, MD
As a chronic inflammatory autoimmune disease, lupus affects many organ systems. The physiology, causes, types, diagnostic challenges, and treatments are discussed, with an emphasis on systemic lupus erythematosus.
William Maidhof, PharmD; and Olga Hilas, PharmD, MPH, BCPS, CGP
Treating the Pain of Lyme Disease and Adopting Lifestyle Change as Therapy
Topics include therapies for chronic Lyme disease, the new "great imitator," and Dr. Dean Ornish’s claim that modifications in lifestyle may enable patients to reverse coronary atherosclerosis without drugs or surgery.
Labels on color-coded syringes for anesthetics must be read carefully.
Matthew Grissinger, RPh, FASCP
Federal Funding Levels Remain Uncertain
The Obama administration's draft plan for Alzheimer's disease includes urgently needed funding and an expansion of clinical trials.
FDA approvals, drug indications, and updates
Ivacaftor (Kalydeco) tablets for cystic fibrosis; vismodegib (Erivedge) for metastatic basal cell carcinoma; and linagliptin/ metformin tablets (Jenta-dueto)
Marvin M. Goldenberg, PhD, RPh, MS
A Breakthrough Therapy for Systemic Lupus Erythematosus
Belimumab (Benlysta) for systemic lupus erythematosus
Raymond Lamore III, PharmD; Sapna Parmar, PharmD; Khilna Patel, PharmD Candidate; and Olga Hilas, PharmD, MPH, BCPS, CGP